MONROVIA, Calif. --(BUSINESS WIRE)--Jan. 9, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical

MONROVIA, Calif. --(BUSINESS WIRE)--Jan. 11, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2022 corporate priorities and anticipated

US Patent Issued for Novel G-CSF with Improved Pharmaceutical Properties Created by Protein Design Automation Technology

Xencor Gives Panel Presentation and Company Update at BIO InvestorForum; Announces Recent Close of $20 Million in Financing MONROVIA, CA – October 18, 2005 – Xencor, Inc., a biotherapeutics company developing protein therapeutics and antibody drugs, announced today that Bassil Dahiyat, Ph.D.,

Xencor Files Registration Statement for Proposed Initial Public Offering MONROVIA, Calif., October 11, 2013— Xencor, Inc. today announced the filing of a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its

Xencor Expands Series E Financing to $60 Million MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, a company developing protein and antibody therapeutics, today announced that it raised an additional $15 million in an extension of its Series E financing, bringing the total raised in this round to $60

Xencor Expands Protein Optimization Technology To Develop Next-Generation Biotechnology Products (BW Healthwire)–February 20, 2002—Monrovia, CA – February 20, 2002 – Xencor today announced that it has signed licensing agreements with the California Institute of Technology and Pennsylvania State

Xencor Expands Management Team; Leverages $50 Million Series C Financing to Fuel Development Efforts (BW Healthwire)–July 19, 2001—Xencor today announced that E.William Radany, Ph.D. has joined the company as Chief Business Officer and Joyce L. Morrison has joined as Vice President, Intellectual

Xencor Expands Management Team To Lead Drug Discovery And Protein Optimization Programs (BW Healthwire)–October 09, 2001—Xencor today announced that Stephen K. Doberstein, Ph.D. has joined as Vice President, Chemical Biology and Robert E. Pacifici, Ph.D.

-- Second agreement with Janssen on bispecific antibodies directed toward the CD28 co-stimulatory receptor on T cells -- -- Xencor to receive $100 million upfront payment and $25 million equity investment and is eligible for a mid-teen to low-twenties percent royalty for plamotamab and potential